Key facts
- It has raised $2.1M; the latest was Later Stage VC ($100K) in Apr 2025.
- Notable investors include Creative Destruction Lab, US National Science Foundation, U.S. Department of Energy, University of Toronto, Innovation Works — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Myris Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Myris Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Myris Therapeutics
Developer of polymer-based antibody drug conjugates designed to create next-generation medicines. The company offers drug loading conjugates built using growing polymer technology, with enhanced solubility, improved payload attachment control, increased stability, and adaptable polymer structures for varied therapeutic design, enabling oncology researchers and biopharmaceutical developers to access flexible payload attachment, improved stability, and precise targeting across diverse cancer pathways.
- Sector
- Healthcare
- HQ
- Sharpsburg, PA, United States
- Founded
- 2016
- Employees
- 23
- Website
- myristx.com/
- Ownership
- Privately Held (backing)
Myris Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Myris Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Myris Therapeutics in its N-PORT filings yet. We sweep new filings monthly.